Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
The stock climbed after investors saw encouraging signs from a similar program.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.